{"doi":"10.1016/j.kint.2020.06.024","title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment","abstract":"The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD. The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD. This is the first Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for Diabetes Management in Chronic Kidney Disease. The guideline comes at a pivotal time, with substantial growth in the public health burden of diabetes and chronic kidney disease (CKD), and with recent development of new therapies applicable to this population.1Afkarian M. Zelnick L.R. Hall Y.N. et al.Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014.JAMA. 2016; 316: 602-610Crossref PubMed Scopus (505) Google Scholar,2Alicic R.Z. Rooney M.T. Tuttle K.R. Diabetic kidney disease: challenges, progress, and possibilities.Clin J Am Soc Nephrol. 2017; 12: 2032-2045Crossref PubMed Scopus (1020) Google Scholar The goal of the new guideline is to provide evidence-based recommendations and practice points to optimize the clinical care of people with diabetes and CKD by integrating new therapies with existing management approaches. The guideline was written by an international Work Group that included 2 patients and was diverse in clinical expertise, supported by a dedicated Evidence Review Team and professional KDIGO staff. The Work Group aimed to generate a useful resource for clinicians and patients that addressed relevant questions with actionable recommendations, took on","journal":"Kidney International","year":2020,"id":49191,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":283,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9229,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":231199,"name":"Maria Luiza Caramori","orcid":"0000-0001-6082-5934","position":1,"is_corresponding":false},{"id":1143,"name":"Juliana C.N. Chan","orcid":"0000-0003-1325-1194","position":2,"is_corresponding":false},{"id":232682,"name":"Hiddo J.L. Heerspink","orcid":"0000-0002-3126-3730","position":3,"is_corresponding":false},{"id":238886,"name":"Clint Hurst","orcid":null,"position":4,"is_corresponding":false},{"id":236347,"name":"Kamlesh Khunti","orcid":"0000-0003-2343-7099","position":5,"is_corresponding":false},{"id":236348,"name":"Adrian Liew","orcid":"0000-0002-0963-6270","position":6,"is_corresponding":false},{"id":236349,"name":"Erin D. Michos","orcid":"0000-0002-5547-5084","position":7,"is_corresponding":false},{"id":236350,"name":"Sankar D. Navaneethan","orcid":"0000-0002-4953-7795","position":8,"is_corresponding":false},{"id":238887,"name":"Wasiu A. Olowu","orcid":null,"position":9,"is_corresponding":false},{"id":238888,"name":"Tami Sadusky","orcid":null,"position":10,"is_corresponding":false},{"id":22843,"name":"Nikhil Tandon","orcid":"0000-0003-4604-1986","position":11,"is_corresponding":false},{"id":231214,"name":"Katherine R. Tuttle","orcid":"0000-0002-2235-0103","position":12,"is_corresponding":false},{"id":74376,"name":"Christoph Wanner","orcid":"0000-0001-9507-5301","position":13,"is_corresponding":false},{"id":236351,"name":"Katy G. Wilkens","orcid":"0000-0002-1281-4541","position":14,"is_corresponding":false},{"id":236352,"name":"Sophia Zoungas","orcid":"0000-0003-2672-0949","position":15,"is_corresponding":false},{"id":236353,"name":"Lyubov Lytvyn","orcid":"0000-0003-4425-2982","position":16,"is_corresponding":false},{"id":85802,"name":"Jonathan C. Craig","orcid":"0000-0002-2548-4035","position":17,"is_corresponding":false},{"id":236354,"name":"David J. Tunnicliffe","orcid":"0000-0003-3270-3475","position":18,"is_corresponding":false},{"id":236355,"name":"Martin Howell","orcid":"0000-0001-9740-712X","position":19,"is_corresponding":false},{"id":2060,"name":"Marcello Tonelli","orcid":"0000-0002-0846-3187","position":20,"is_corresponding":false},{"id":109010,"name":"Michael Cheung","orcid":"0000-0002-6233-2831","position":21,"is_corresponding":false},{"id":236356,"name":"Amy Earley","orcid":"0000-0003-3200-2492","position":22,"is_corresponding":false},{"id":42050,"name":"Peter Rossing","orcid":"0000-0002-1531-4294","position":23,"is_corresponding":false},{"id":231201,"name":"Ian H. de Boer","orcid":"0000-0003-1571-7592","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-18T20:36:25.163232Z","pmid":"32653403","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}